Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+/- and LDLR-/- ) Yucatan Miniature Pigs.

Burke AC, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Barrett PHR, Newton RS, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2018 Feb 15. pii: ATVBAHA.117.310676. doi: 10.1161/ATVBAHA.117.310676. [Epub ahead of print]

PMID:
29449335
2.

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr-/- Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.

Samsoondar JP, Burke AC, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Pinkosky SL, Newton RS, Huff MW.

Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):647-656. doi: 10.1161/ATVBAHA.116.308963. Epub 2017 Feb 2.

3.

Treatment with didemnin B, an elongation factor 1A inhibitor, improves hepatic lipotoxicity in obese mice.

Hetherington AM, Sawyez CG, Sutherland BG, Robson DL, Arya R, Kelly K, Jacobs RL, Borradaile NM.

Physiol Rep. 2016 Sep;4(17). pii: e12963. doi: 10.14814/phy2.12963.

4.

Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia.

Pang DK, Nong Z, Sutherland BG, Sawyez CG, Robson DL, Toma J, Pickering JG, Borradaile NM.

Pharmacol Res Perspect. 2016 Apr 14;4(3):e00233. doi: 10.1002/prp2.233. eCollection 2016 Jun.

5.

Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.

Assini JM, Mulvihill EE, Burke AC, Sutherland BG, Telford DE, Chhoker SS, Sawyez CG, Drangova M, Adams AC, Kharitonenkov A, Pin CL, Huff MW.

Endocrinology. 2015 Jun;156(6):2087-102. doi: 10.1210/en.2014-2003. Epub 2015 Mar 16.

PMID:
25774553
6.

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity.

Bojic LA, Telford DE, Fullerton MD, Ford RJ, Sutherland BG, Edwards JY, Sawyez CG, Gros R, Kemp BE, Steinberg GR, Huff MW.

J Lipid Res. 2014 Jul;55(7):1254-66. doi: 10.1194/jlr.M046037. Epub 2014 May 26.

7.

Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.

Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Tirona RG, Yin H, Pickering JG, Huff MW.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):52-60. doi: 10.1161/ATVBAHA.113.301830. Epub 2013 Oct 24.

8.

Naringenin prevents cholesterol-induced systemic inflammation, metabolic dysregulation, and atherosclerosis in Ldlr⁻/⁻ mice.

Assini JM, Mulvihill EE, Sutherland BG, Telford DE, Sawyez CG, Felder SL, Chhoker S, Edwards JY, Gros R, Huff MW.

J Lipid Res. 2013 Mar;54(3):711-24. doi: 10.1194/jlr.M032631. Epub 2012 Dec 26.

9.

Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance.

Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, St-Pierre P, Marette A, Huff MW.

Diabetes. 2011 May;60(5):1446-57. doi: 10.2337/db10-0589. Epub 2011 Apr 6.

10.

Molecular biodiversity and population structure in common ash (Fraxinus excelsior L.) in Britain: implications for conservation.

Sutherland BG, Belaj A, Nier S, Cottrell JE, P Vaughan S, Hubert J, Russell K.

Mol Ecol. 2010 Jun;19(11):2196-211. doi: 10.1111/j.1365-294X.2009.04376.x. Epub 2010 Apr 30.

PMID:
20465580
11.

Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.

Mulvihill EE, Assini JM, Sutherland BG, DiMattia AS, Khami M, Koppes JB, Sawyez CG, Whitman SC, Huff MW.

Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):742-8. doi: 10.1161/ATVBAHA.109.201095. Epub 2010 Jan 28.

12.

Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

Mulvihill EE, Allister EM, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Markle JM, Hegele RA, Huff MW.

Diabetes. 2009 Oct;58(10):2198-210. doi: 10.2337/db09-0634. Epub 2009 Jul 10.

13.

Trans-specific S-RNase and SFB alleles in Prunus self-incompatibility haplotypes.

Sutherland BG, Tobutt KR, Robbins TP.

Mol Genet Genomics. 2008 Jan;279(1):95-106. Epub 2007 Nov 8.

PMID:
17989997
14.

Self-(in)compatibility of the almonds P. dulcis and P. webbii: detection and cloning of 'wild-type Sf ' and new self-compatibility alleles encoding inactive S-RNases.

Bosković RI, Tobutt KR, Ortega E, Sutherland BG, Godini A.

Mol Genet Genomics. 2007 Dec;278(6):665-76. Epub 2007 Sep 27.

PMID:
17899198
15.

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.

Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW.

J Lipid Res. 2007 Mar;48(3):699-708. Epub 2006 Nov 27.

16.

A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.

Telford DE, Lipson SM, Barrett PH, Sutherland BG, Edwards JY, Aebi JD, Dehmlow H, Morand OH, Huff MW.

Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2608-14. Epub 2005 Oct 6.

Supplemental Content

Loading ...
Support Center